Screener
Crinetics Pharmaceuticals CRNX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's interest income?
- Crinetics Pharmaceuticals (CRNX) reported interest income of $12.66M in Q1 2026.
- How has Crinetics Pharmaceuticals's interest income changed year-over-year?
- Crinetics Pharmaceuticals's interest income decreased by 14.6% year-over-year, from $14.83M to $12.66M.
- What is the long-term trend for Crinetics Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's interest income has grown at a 326.6% compound annual growth rate (CAGR), from $157K to $51.99M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Crinetics Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude